Loading the company…
Loading the company…
In the last ten years FDA made 9 decisions for Sirtex Medical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (4). The latest was on 2026-07-09.
| Family | Decisions on record |
|---|---|
| Tumor & fibroid embolization | 9 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-07-09 | PMA | P220020-S008 | Lava Liquid Embolic System (Lava LES) · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-09-03 | PMA | P220020-S005 | Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit · Location Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-08-05 | PMA | P220020-S007 | Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit · Labeling Change - Indications/instructions/shelf life/tradename |
| 2025-06-02 | PMA | P220020-S006 |
In 2025, Sirtex Medical reported engagement with 1,621 surgeons and other clinicians in the states MedaRep covers, worth $2.6M in consulting, speaking, meals and travel for its device products, the most in California ($455K to 177). Royalties are left out.
| Lava Liquid Embolic System (Lava LES) · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-03-20 | PMA | P220020-S004 | Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Sirtex Medical.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($455K, 177 engaged), Florida ($403K, 142 engaged), New York ($220K, 102 engaged), Georgia ($216K, 33 engaged), Texas ($180K, 275 engaged).